Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern

In patients with atypical hemolytic uremic syndrome (aHUS), complement blocking by eculizumab rapidly halts the process of thrombotic microangiopathy and it is associated with clear long-term hematologic and renal improvements. Eculizumab treatment consists of a 4-week initial phase with weekly IV a...

Descripción completa

Detalles Bibliográficos
Autores principales: García Monteavaro, Camino, Peralta Roselló, Carmen, Quiroga, Borja, Baltar Martín, José María, Castillo Eraso, Lorena, de Álvaro Moreno, Fernando, Martínez Vea, Alberto, Visus-Fernández de Manzanos, María Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153492/
https://www.ncbi.nlm.nih.gov/pubmed/28025630
http://dx.doi.org/10.1155/2016/7471082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153492/
https://www.ncbi.nlm.nih.gov/pubmed/28025630
http://dx.doi.org/10.1155/2016/7471082

Ejemplares similares